Intranasal racemic ketamine maintenance therapy for patients with treatment-resistant depression: a naturalistic feasibility study.
BMC psychiatry January 7, 2025 Katelyn Halpape, Raelle Pashovitz, Annabelle Wanson et al. 4 citations
For patients with treatment-resistant depression who respond to intranasal racemic ketamine in the hospital, continuing the same treatment as an outpatient maintenance therapy appears feasible and well tolerated. In a small pilot program involving five patients who completed up to 14 treatment sessions over 192 days, depressive symptoms decreased or remained stable and quality of life increased or remained stable. The average dose was 220 mg (range 100 to 400 mg). No serious adverse events occurred; reported side effects included anxiety and nausea, and slight blood pressure increases required no intervention. Because of the very small sample, no conclusions about effectiveness can be drawn, and further research is needed.